Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Hypertension. 2020 Sep 28;76(5):1461–1469. doi: 10.1161/HYPERTENSIONAHA.120.15928

Figure 4. Impact of chronic adrenoceptor antagonism on NCC regulation in Dahl Salt-Sensitive (DSS) hypertension.

Figure 4.

(A) total WNK1 and WNK4 expression and respective immunoblots, (B) total SPAK and OxSR1 expression and respective immunoblots and, (C) total pSPAK (S373)/pOxSR1 (S325) expression and pSPAK (T233)/pOxSR1 (T185) expression and respective immunoblots in groups of 3-month old male s.c. saline/DMSO vehicle treated DSS rats or groups of DSS rats that received a subcutaneous (s.c.) infusion of terazosin (Teraz) or propranolol (Pro) dissolved in saline/DMSO during a 21-day high salt (HS, 4% NaCl) diet. N=5/6 per group mean ± SD. Treatment group protein expression was compared to the same untreated HS group expression via individual blots to avoid comparing separate immunoblots. Protein expression is shown as fold change with untreated DSS HS target protein expression for each individual blot set to 1. Differences in untreated DSS HS and HS + adrenoceptor antagonist target protein expression were determined using a student’s t test. *P < 0.05 vs. respective DSS HS group.